Literature DB >> 10969627

Comparison of clinical, morphological, and prognostic features in hypertrophic cardiomyopathy between Japanese and western patients.

T Chikamori1, Y L Doi, M Akizawa, Y Yonezawa, T Ozawa, W J McKenna.   

Abstract

Apical hypertrophic cardiomyopathy appears to be more common in Japan than in the West. Explanations for this difference include variable methods and criteria for the diagnosis. To assess morphological, clinical, and prognostic differences, 45 consecutive Japanese and 45 age- and gender-matched Western patients with hypertrophic cardiomyopathy were evaluated in two referral institutions by the same individuals. The diagnosis of hypertrophic cardiomyopathy was based on the echocardiographic demonstration of unexplained left ventricular hypertrophy. Patients were aged 8 to 64 years (mean 50); there were 66 males and 24 females. The pattern of left ventricular hypertrophy was similar in Japanese and Western patients: asymmetric septal 64 vs. 76%, concentric 22 vs. 13%, and apical 13 vs. 11% (p = NS). The incidence of an echocardiographic or Doppler calculated left ventricular gradient of > 30 mmHg was similar (11 vs. 18%; p = NS). The maximal left ventricular wall thickness was greater in Western patients (23 +/- 7 vs. 20 +/- 4 mm; p = 0.03), but was not different when adjusted for body surface area. Clinical features including incidence of family history and ventricular tachycardia during 24-h ambulatory electrocardiography were similar. During follow-up (4.9 +/- 4.0 years for Western vs. 4.4 +/- 2.0 years for Japanese), disease-related mortality was worse in Western patients (p < 0.05; 10 versus 2 patients). This evaluation, using the same diagnostic methods and criteria, reveals a worse prognosis in Western patients despite a similar clinical and morphological spectrum of hypertrophic cardiomyopathy.

Entities:  

Mesh:

Year:  1992        PMID: 10969627     DOI: 10.1002/clc.4960151108

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  8 in total

Review 1.  Multimodality imaging in apical hypertrophic cardiomyopathy.

Authors:  Rosario Parisi; Francesca Mirabella; Gioel Gabrio Secco; Rossella Fattori
Journal:  World J Cardiol       Date:  2014-09-26

2.  Comparison of the clinical features of apical hypertrophic cardiomyopathy versus asymmetric septal hypertrophy in Korea.

Authors:  Hyun Suk Yang; Jae-Kwan Song; Jong-Min Song; Duk-Hyun Kang; Cheol Whan Lee; Myeong-Ki Hong; Jae-Joong Kim; Seong-Wook Park; Seung-Jung Park
Journal:  Korean J Intern Med       Date:  2005-06       Impact factor: 2.884

3.  Cheating the CHA2DS2-VASc Score: Thromboembolism in Apical Hypertrophic Cardiomyopathy.

Authors:  Robin A P Weir; Nicola MacKenzie; Colin J Petrie
Journal:  Case Rep Cardiol       Date:  2014-11-20

4.  Apical Hypertrophic Cardiomyopathy Among Non-Asians: A Case Series and Review of the Literature.

Authors:  Karan Kapoor; Amal Chaudhry; Matthew C Evans; Amish Sura
Journal:  Cardiol Res       Date:  2016-02-20

5.  All That Glitters is not Gold: Apical Hypertrophic Cardiomyopathy Mimicking Acute Coronary Syndrome.

Authors:  Umashankar Lakshmanadoss; Abhishek Kulkarni; Shobana Balakrishnan; Nidhi Shree; Kishore Harjai; Dinesh Jagasia
Journal:  Cardiol Res       Date:  2012-05-20

6.  Late onset apical hypertrophic cardiomyopathy: a case report.

Authors:  Patrick Doeblin; Rolf Gebker; Burkert Pieske; Sebastian Kelle
Journal:  Eur Heart J Case Rep       Date:  2020-12-12

7.  Yamaguchi syndrome: A mimicer of acute coronary syndrome.

Authors:  Manish Ruhela; Rakesh Kumar Ola; Neeraj Chaturvedi; Rajeev Bagarhatta
Journal:  J Family Med Prim Care       Date:  2022-05-14

8.  Morphological and Electrical Characteristics in Patient with Hypertrophic Cardiomyopathy: Quantitative Analysis of 864 Korean Cohort.

Authors:  Sung-Hwan Kim; Yong-Seog Oh; Gi-Byoung Nam; Kee-Joon Choi; Dae Hee Kim; Jong-Min Song; Duk-Hyun Kang; Jae-Kwan Song; You-Ho Kim
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.